Packaging Defect Forces Merck & Co., Inc. (MRK) To Recall All Lots Of High BP Drug Liptruzet In U.S.
1/15/2014 6:37:51 AM
Merck said today that it was recalling all lots of Liptruzet, its combination of the cholesterol-lowering drugs ezetimibe and atorvastatin, in the US. The company said the recall was due to a packaging defect which could potentially allow air and moisture to affect the quality of the drug, though the company said “the likelihood of the packaging defects decreasing the effectiveness of Liptruzet on a patient’s lipid profile or negatively impacting the safety of the product is remote.” To date there have been no adverse events or product complaints reported to the company.
Help employers find you! Check out all the jobs and post your resume.
comments powered by